FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
about
Heliox inhalation therapy for bronchiolitis in infantsRationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virusSocial, economic, and health impact of the respiratory syncytial virus: a systematic searchDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab ProphylaxisRespiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING StudyEpidemiology of respiratory syncytial virus infection in preterm infants.Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort.Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).Preventing hospitalizations for respiratory syncytial virus infectionRespiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study.Relative frequency, Possible Risk Factors, Viral Codetection Rates, and Seasonality of Respiratory Syncytial Virus Among Children With Lower Respiratory Tract Infection in Northeastern Brazil.The Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.Risk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSW: a whole-of-population-based cohort studyManagement of acute viral bronchiolitis in children: Evidence beyond guidelines.Prevention of respiratory syncytial virus infectionBurden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.A review of cost-effectiveness of palivizumab for respiratory syncytial virus.Respiratory syncytial virus--a comprehensive review.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Prematurity and the burden of influenza and respiratory syncytial virus disease.The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis.Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010-2014: the importance of birth month.Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.Risk factors for severe respiratory syncytial virus lower respiratory tract infectionOutcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.Risk factors for bronchiolitis, recurrent wheezing, and related hospitalization in preterm infants during the first year of life.Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants.RSV infection among children born moderately preterm in a community-based cohort.Rebuttal: palivizumab for the prevention of respiratory syncytial virus infectionCan we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
P2860
Q24187117-5E086573-525D-4737-A8E0-9893C36841D3Q26825438-08C2A7AF-9C99-48AC-80D1-CA49B53A83A5Q26852865-FDFB38B4-71AB-4CF8-8D21-672381D565FEQ28072535-3D8D5340-A1C0-4B78-8223-7E3FE8FEC1AEQ30251560-E6200331-73C4-465C-95C5-165806B7E441Q33582499-0431A438-DA59-4DEA-A9B1-F1CA5D32EA55Q33628327-57927D5A-D488-4D74-AB80-2A08108839BDQ33630047-E2E95E91-433A-4BE7-8A39-3D307DA3B55BQ34240719-C182AF93-C2FF-45D4-A94D-C64B3482D233Q34313010-B6A58741-6BBA-4EA1-B4FA-F337C5668701Q34379517-829F109A-4706-4CED-A665-364AAAA25AA1Q34884984-BA5B6EBD-A2AB-4787-B29B-BD31BD0DD777Q35119631-A712A4B3-8305-4637-9404-51926F55F838Q35587298-604F9882-F4FF-45A6-B7D5-2F5A53BB8586Q35673550-805CE034-C6EE-4C39-8B0A-7AAA1FD6C617Q35678345-EEBFA0FC-8330-462D-BE86-D83280C5FC4CQ36054311-A80AE0AE-98F9-4CF3-9C6A-63891371A37CQ36082195-AB2A2AD3-D917-4664-BF2F-6AA1AF9075F9Q36193981-6A98236B-DCB0-4611-A7A9-C25DEAE606D1Q36822256-C4C8946A-CEE8-4C99-BE80-F4E077DA9EFDQ37056532-EFB526A7-FA56-4ED6-9E44-A36E366E131EQ37063662-84822C0E-5B2E-4371-939A-BBB2F99C894FQ37105886-9BE500FB-8978-47C6-8663-3747841FBB0AQ37429454-5ABEA1A8-962E-45DA-AA0D-0983AB6909DAQ37591891-75DE0E5F-F2E0-44E2-8C08-335F05428BD4Q38058838-14025318-7BAC-49F9-B313-F25C52395C85Q38098094-6D5F4070-BD38-4B0B-8DD9-1DA94264C168Q38604949-243047F5-DBDA-4858-9E72-14576DF59D03Q38637989-F14E3C34-E653-4ABE-B6EB-D653C3B09BF9Q38769295-B6895070-466D-4B9B-9B5C-BEA7C3646759Q38903197-A1641105-CB68-4B41-8A73-40C816235CABQ40122511-B2966834-1977-474A-8D97-0A779D4BD983Q40412523-DA07B2FF-B91B-4677-A0A7-911DB0C19CB3Q40543961-485E9E20-BC32-46F2-87C9-6C0F71C07D57Q40882601-F2693843-C5A4-4E78-B323-95EA2273EEECQ41199983-2D1F1A74-B99B-4101-92CD-F898DB13E459Q41753179-04325CA5-D0F2-4C52-8F44-86488C272D4CQ42031296-0620BEEF-B401-49CD-89D4-CFDA071C39EAQ42204657-59EBBE2E-EA27-4E86-98BE-15FFB2440DD7Q42682504-7FFD3998-677F-4BF4-ABF2-9551925FBB1F
P2860
FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@en
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@nl
type
label
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@en
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@nl
prefLabel
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@en
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@nl
P2093
P1476
FLIP-2 Study: risk factors lin ...... ational age of 32 to 35 weeks.
@en
P2093
Belén Fernández-Colomer
Eduardo Doménech-Martínez
IRIS Study Group
Iñaqui Echaniz-Urcelay
José Figueras-Aloy
José Quero-Jiménez
Juana Guzmán-Cabañas
Xavier Carbonell-Estrany
P304
P356
10.1097/INF.0B013E3181710990
P577
2008-09-01T00:00:00Z